Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers

por Drilon, Alexander, Schoenfeld, Adam J., Arbour, Kathryn C., Litvak, Anna, Ni, Ai, Montecalvo, Joseph, Yu, Helena A., Panora, Elizabeth, Ahn, Linda, Kennedy, Maureen, Haughney-Siller, Anne, Miller, Vincent, Ginsberg, Michelle, Ladanyi, Marc, Arcila, Maria, Rekhtman, Natasha, Kris, Mark G., Riely, Gregory J.
Publicado 2019